causing pulmonary hypertension (PHTN) and right ventricular (RV) strain. 6 However, there is limited information on the effects of i.v. ETOH on heart function, pulmonary and systemic haemodynamics, 7 and in clinical conditions similar to those encountered during therapeutic procedures.
We have studied the causal relationship between the i.v. administration of ETOH and alterations in systemic and pulmonary haemodynamics, and examined the duration of such changes in an intact porcine model. An additional purpose was to create a basis for investigating possible treatment in such catastrophes.
After approval by the University of Florida Institutional Animal Care and Use Committee, eight domestic pigs (45 -50 kg) were studied and handled according to NIH guidelines. The animals were anaesthetized with isoflurane in O 2 50%. Animals were mechanically ventilated to maintain normocarbia. A 7-French (Fr), pressure-tipped, flotation pulmonary artery catheter (Millar Instruments Inc., Houston, TX, USA) was inserted via the right internal jugular vein into the main pulmonary artery. A 7-Fr, triple lumen, central venous catheter was placed through the left internal jugular vein. The left carotid artery was exposed, and a 5-Fr pressure-tipped catheter (Millar Instruments Inc.) was placed and advanced into the ascending aorta for continuous arterial pressure monitoring. A median sternotomy was then performed and the heart placed in a pericardial cradle. A 5-Fr pressure-tipped catheter was inserted via a small stab wound into the RV cavity for measurement of RV pressure (RVP) and RV dP/ dT. Cardiac output (CO) was measured with a 10 mm perivascular ultrasound probe placed in the main pulmonary artery. All animals were allowed to stabilize (arterial pressure, temperature) for 60 min after the surgical preparation before data collection. Haemodynamic measurements included systemic mean arterial pressure (MAP), mean pulmonary artery pressure (MPAP), RVP, central venous pressure (CVP), pulmonary artery occlusion pressure (PAOP), and CO. Pulmonary and systemic haemodynamics and RV dP/dT, as an index of contractility, were measured. PVR and systemic vascular resistance (SVR) were calculated using standard formulas.
Undiluted ETOH was infused via a central venous catheter at a rate of 2 ml min 21 (approximately 50 mg kg 21 min
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) until a two-fold increase in MPAP was reached or a maximum of 20 ml were infused. Two previous animals (not included in this study) suffered from acute cor pulmonale when a dose of 5 ml of ETOH was administered as a rapid i.v. bolus (as is frequently administered for ablation procedures) and could not be resuscitated. Therefore, we decided to proceed with the slower infusion of ETOH. When the target MPAP was reached, the infusion was discontinued and the animals observed until haemodynamics returned to within 10% of baseline.
Data were collected at baseline, when the target MPAP was achieved, and after discontinuation of the infusion until haemodynamics returned to within 10% of baseline. After discontinuation of ETOH, the animals received only an infusion of 2 ml kg 21 of normal saline (NS). At the end of the experiment, the animals were euthanized. Data were expressed as mean (SD). A two-way analysis of variance was used, followed by Student -Newman -Keuls test for multiple comparisons. A P-value of ,0.05 was considered significant.
A rate of 50 mg kg 21 (approximately 2.5 ml of ETOH per min) was sufficient to induce significant PHTN within 3 min. The infusion of ETOH achieved a two-fold elevation in MPAP at a mean dose of 188 (22) 6 8 the magnitude of which are dose-and concentration-dependent. The mechanisms for ETOHinduced pulmonary vasoconstriction are believed to involve the release of secondary mediators such as catecholamines or histamines, 7 or arachidonic acid metabolites. 9 The effects of ETOH in the vasculature are complex and involve both vasoconstriction and vasodilatation. 10 It was demonstrated that intracellular Ca 2þ in a vascular smooth muscle cell preparation increased with ETOH, even in the presence of Ca 2þ channel blockade.
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The effects of ETOH on pulmonary and systemic haemodynamics in our study were short-lived and vascular resistances returned to baseline values approximately 10 min after the discontinuation of ETOH, whereas depression of RV contractility persisted. The absence of hypotension and preservation of CO during the phase of marked PHTN and RV dysfunction can be explained by the increased sympathetic outflow, as evidenced by a 40% increase in HR, with the calculated stroke volume essentially unchanged.
Our study differs from previous investigations in that the concentration of ETOH used is that commonly used in ablation procedures. 1 -3 We established that 50 mg kg
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given at approximately 2.5 ml min 21 was sufficient to induce significant PHTN within 3 min. This result, extrapolated to clinical use, suggests that a slow rate of ETOH infusion should be considered, in conjunction with careful monitoring of the patient's haemodynamic status, in conditions where the risk of intravascular absorption is high.
In our study, systemic haemodynamics were relatively preserved probably because of an otherwise intact cardiovascular system in our experimental animals. We postulate that in otherwise healthy patients, small amounts of ETOH may not have a measurable clinical effect, as brief, moderate increases in PVR may be tolerated without haemodynamic compromise. In contrast, patients with preexisting PHTN or myocardial disease will be more susceptible to haemodynamic instability.
Placement of enterogastric tubes
Editor-Enterogastric tubes are widely used in clinical practice to facilitate gastric emptying or the administration of enteral feed and oral medication. Morbidity associated with their use is uncommon but is well recognized.
1 -3 A report from the National Patient Safety Authority (NPSA) states that 11 deaths occurred from misplaced NG tubes between 2003 and 2004. 4 We would like to report the results of an audit undertaken in two teaching hospitals regarding the knowledge of enterogastric tube markings among anaesthetists. Several commonly used enterogastric tubes have markings along the length to indicate distance from the tip of the tube; however, they are not standardized by the manufacturers. The first distance marking (a single bar) found on tubes by the manufacturers Portex (Hythe, UK), Rüsch (Gauting, Germany), and Flocare (Nutricia,
